In a small study of recurrent platinum sensitive ovarian cancer patients, BRCA1/2 mutation carriers demonstrated a significant response to repeat carboplatin with dose dense paclitaxel regimens, compared to sporadic patients, suggesting that this drug combination is particularly effective in BRCA1/2-related disease [28], and potentially by extension to HR deficient tumors. This evidence concerns the gene BRCA1 and ovarian carcinoma.